(Q40397936)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

20 September 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells (English)

1 reference

20 September 2017

1 reference

C Yu

1

1 reference

20 September 2017

G Dasmahapatra

series ordinal

2

1 reference

20 September 2017

P Dent

series ordinal

3

1 reference

20 September 2017

S Grant

series ordinal

4

1 reference

20 September 2017

publication date

1 September 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

19

1 reference

20 September 2017

issue

9

1 reference

20 September 2017

page(s)

1579-1589

1 reference

The biology of chronic myeloid leukemia

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Histone acetylases--versatile players

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Induction of Apoptosis in BCR/ABL+ Cells By Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Development of anticancer drugs targeting the MAP kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

The cleavage of Akt/protein kinase B by death receptor signaling is an important event in detachment-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

inferred from DOI database lookup

7 January 2021

based on heuristic

Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403868

inferred from DOI database lookup

7 January 2021

based on heuristic

Regulation and function of the JNK subgroup of MAP kinases

1 reference

COCI

https://opencitations.net/index/api/v1/references/10.1038/SJ.LEU.2403868

30 December 2023

Identifiers

DOI

10.1038/SJ.LEU.2403868

1 reference

Dimensions Publication ID

20 September 2017

1034970687

0 references

1 reference